Abstract
Purpose of Review
Use of inhaled aerosols allows selective treatment of the lungs by achieving high drug concentrations in the airways while minimizing systemic effects. Inhaled long acting beta 2 agonists (ILAB) produce a more rapid onset of action than oral delivery and are convenient and safe for the most patients. Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough, and mucus buildup. It is the sixth most common cause of death worldwide and is associated with significant healthcare costs.
Recent Findings
ILAB have demonstrated to be very effective in the treatment of asthma and COPD. They work through sustained muscle relaxation and are potent bronchodilators. ILAB’s are widely prescribed to manage the symptoms of COPD and asthma when short-acting agents alone are no longer sufficient.
Summary
Twice-daily treatment with an inhaled ILAB or once-a-day treatment with the Ultra LABA is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline of disease, improving lung function, and preventing and treating exacerbations. There is no evidence to support the use of ILAB or the Ultra LABA, alone or in combination with a corticosteroid, as a first line agent for treatment of COPD or asthma.
Similar content being viewed by others
References
Johnson M, Rennard S. Alternative mechanisms for long acting B2 adrenergic agonists in COPD. Chest. 2001;120:258–70.
Tashkin D, Fabbri LM. Long acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149–63.
Guerra S. Overlap of asthma and chronic obstructive pulmonary disease. Current Opinion Pulmonary Medicine. 2005;11:7–13.
Niewoehnir DE. Clinical practice: outpatient management of severe COPD. N Engl J Med. 2010;362:1407–16.
Albouaini K, Mohammed A, Alahmar A, Mohaned E. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Inter J Chronic Obstructive Pulmonary Disease. 2007;2(4):535–540
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015 Version. Published January 2015
Breekvelot-Postmaa NS, Koerselmanj EJA, Lammers J-WJ, Herrings RMC. Enhanced persistence with tiotropium compared with other drugs in COPD. Respiratory Med. 2007;101:1398–405.
Brovana Package Insert. Sunovion Pharmaceuticals, Inc. 2011, www.sunovion.com
Arcapta Package Insert. Novartis 2012 http://www.us.novartis.com
Foradil Package Insert. Mereck & Co., Inc. 2010. https://www.merck.com/product/usa/pi.../f/foradil/foradil_pi.pdf.
Serevent Package Insert. GlaxoSmithKline 2010 Available at: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Serevent_Diskus/pdf/SEREVENT-DISKUS-PI-MG.PDF. Accessed July 6, 2015.
Advair Package Insert. GlaxoSmithKline 2014 https://www.gsksource.com/.../Advair.../ADVAIR-DISKUS-PI-MG.PDF
Dulera Package Insert. Mereck & Co., Inc. 2014. https://www.merck.com/product/usa/pi.../d/dulera/dulera_pi.pdf
Symbicort Package Insert. AstraZeneca 2012. Available at; http://www.azpicentral.com/symbicort/symbicort.pdf#page=1. Accessed April 21, 2015.
Bourbeau J, Barlett SJ. Patient adherence in COPD. Thorax. 2008;63:831–8.
Calverley PM, Anderson JA, Celi B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestoo J. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. NEJM. 2007;356:775–89.
Au DH, Udris EM, Curtis JR, McDonnell MB, Finn SD. Association between chronic heart failure and inhaled beta-2-adrenoreceptor agonists. Am Heart J. 2004;148(5):915–20.
Rodingo GI, Nanni LI, Rodriguez-Roisin R. Safety of long-acting B-agonists in stable COPD. Chest. 2008;133:1079–87.
Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R, Higgins M. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Current Medications Respiratory Opinion. 2009;25:463–70.
National Heart, Lung and Blood Institute. Health Professionals Practice Guidelines May?2015. https://www.nhlbi.nih.gov/health-pro.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The author declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Pharmacology of Acute Care
Rights and permissions
About this article
Cite this article
Romard, R.A. Management of Chronic Pulmonary Obstructive Disease: a Review of Long Acting Beta 2 Agonists. Curr Emerg Hosp Med Rep 5, 16–20 (2017). https://doi.org/10.1007/s40138-017-0127-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40138-017-0127-4